ResearcherUniversity of LondonNo recent work listed

Riccardo Ferro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6532-4856; OpenAlex author ID A5073396282. Sources: OpenAlex.

Their work

Papers: 4 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers

Papers 4

ABCC3 is a novel target for the treatment of pancreatic cancer. First author DOI 10.1016/j.jbior.2019.04.004 ↗
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1191-2 ↗
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Co-author DOI 10.1038/s41388-018-0390-1 ↗
Emerging role of the KRAS-PDK1 axis in pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i31.10752 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Marco Falasca · 3 shared papers, 2018–2019 · strength 0.24
Charlotte E. Edling · 2 shared papers, 2018–2019 · strength 0.15
- Paper Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. DOI 10.1186/s13046-019-1191-2 ↗
- Paper GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increa… DOI 10.1038/s41388-018-0390-1 ↗
Aleksandra Adamska · 2 shared papers, 2018–2019 · strength 0.15
- Paper ABCC3 is a novel target for the treatment of pancreatic cancer. DOI 10.1016/j.jbior.2019.04.004 ↗
- Paper GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increa… DOI 10.1038/s41388-018-0390-1 ↗
Vincenzo De Laurenzi · 2 shared papers, 2018–2019 · strength 0.15
- Paper ABCC3 is a novel target for the treatment of pancreatic cancer. DOI 10.1016/j.jbior.2019.04.004 ↗
- Paper GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increa… DOI 10.1038/s41388-018-0390-1 ↗
Stefano Iacobelli · 1 shared paper, 2019 · strength 0.09
- Paper Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. DOI 10.1186/s13046-019-1191-2 ↗
Alice Domenichini · 1 shared paper, 2019 · strength 0.09
- Paper ABCC3 is a novel target for the treatment of pancreatic cancer. DOI 10.1016/j.jbior.2019.04.004 ↗
Aikaterini Emmanouilidi · 1 shared paper, 2019 · strength 0.09
- Paper Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. DOI 10.1186/s13046-019-1191-2 ↗
Verena Damiani · 1 shared paper, 2019 · strength 0.09
- Paper ABCC3 is a novel target for the treatment of pancreatic cancer. DOI 10.1016/j.jbior.2019.04.004 ↗
Owen James Sansom · 1 shared paper, 2018 · strength 0.07
- Paper GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increa… DOI 10.1038/s41388-018-0390-1 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.